Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the use of definitive radiation to the primary lung lesion prolongs progression-free survival (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC) patients who are subsequently placed on a tyrosine kinase inhibitor (TKI).

Trial Details

NCT ID
NCT06305715
Phase
PHASE2
Sponsor
Medical College of Wisconsin
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Radiation Therapy
  • Targeted TKI therapy
Locations (sample)
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Age ≥18 years.
  • Patient must have a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC).
  • An identifiable primary lung lesion must be present based on the consensus opinion of the medical oncology and radiation oncology investigators.
  • Patient did not previously receive radiation therapy to the primary lung lesion. Previous or concurrent palliative radiation to symptomatic metasta…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →